Open-Label Study of AG10 in Patients With Cardiomyopathy

An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201 The primary objective of this study is to evaluate the long-term safety and tolerability of acoramidis administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who have completed the study AG10-201. This study will be an Open-Label Extension and Safety Monitoring Study of up to 55 male and/or female patients with symptomatic ATTR-CM, ≥18 years of age, who have completed the Phase II Study AG10-201. Enrollment into the study will be followed by visits at Day 14, Day 45, 3 Months and every 3 months thereafter until Month 54. After the Month 54 Visit, clinic visits will be every 6 months. There will be one follow-up visit approximately 30 days after last dose. If all doses are well tolerated, the duration of each patient's participation in the study will continue based on periodic recommendations of the acoramidis Data Monitoring Committee (DMC) and/or registration of the product for the treatment of symptomatic ATTR-CM. The secondary objectives of this study are to characterize the pharmacokinetics (PK) of acoramidis administered orally twice daily in patients with symptomatic ATTR-CM, and to describe the long-term pharmacodynamic (PD) properties of acoramidis as assessed by established assays of transthyretin (TTR) stabilization, including Fluorescent Probe Exclusion (FPE) assay and Western blot, and to describe the PK-PD relationship of acoramidis in adult patients with symptomatic ATTR-CM.